EHR-Based Interventions for Breast and Ovarian Cancer Genetic Testing

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and counseling that may initiate life-saving screenings.

Research Team

Eligibility Criteria

This trial is for people with a family history of breast or ovarian cancer, especially if diagnosed before age 50, and those with specific types of these cancers diagnosed over two years ago. It's not open to anyone who has already had genetic counseling or testing.

Inclusion Criteria

I was diagnosed with serous ovarian cancer over two years ago.

My family has a history of breast cancer before age 50.

I was diagnosed with breast cancer before turning 50 and it has been over two years.

Exclusion Criteria

I have undergone genetic counseling or testing before.

Treatment Details

Interventions

• Sequential EHR Communications (Behavioural Intervention)

Trial Overview The study tests different ways to communicate through electronic health records (EHR) to see which method increases the rate at which people get genetic testing for breast and ovarian cancer predisposition.

Participant Groups

Group I: Sequential Communications Experimental Treatment 1 Intervention

This sequential arm contains three types of communication to be employed following non-response to the previous type. The initial communication will be a direct message to the patient via the MyPennMedicine. The subsequent message will be sent as a text via the Way To Health app(lication). The final communication will be a nudge to the patient's physician which will send upon opening the patient's chart and will remain as a flag thereafter.

Who Is Running the Clinical Trial?

Abramson Cancer Center of the University of Pennsylvania

Lead Sponsor

Trials

360

Recruited

108,000+

Dr. Robert H. Vonderheide

Abramson Cancer Center of the University of Pennsylvania

Chief Executive Officer since 2017

DPhil in Immunology from Oxford University, MD from Harvard Medical School

Dr. Lawrence N. Shulman

Abramson Cancer Center of the University of Pennsylvania

Chief Medical Officer since 2017

MD from Harvard Medical School

Abramson Cancer Center at Penn Medicine

Lead Sponsor

Trials

425

Recruited

464,000+

Dr. Robert H. Vonderheide

Abramson Cancer Center at Penn Medicine

Chief Executive Officer since 2017

MD from Harvard Medical School

Dr. Bonnie Ky

Abramson Cancer Center at Penn Medicine

Chief Medical Officer

MD, MSCE from University of Pennsylvania